Your browser doesn't support javascript.
loading
Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys.
Pegu, Amarendra; Xu, Ling; DeMouth, Megan E; Fabozzi, Giulia; March, Kylie; Almasri, Cassandra G; Cully, Michelle D; Wang, Keyun; Yang, Eun Sung; Dias, Joana; Fennessey, Christine M; Hataye, Jason; Wei, Ronnie R; Rao, Ercole; Casazza, Joseph P; Promsote, Wanwisa; Asokan, Mangaiarkarasi; McKee, Krisha; Schmidt, Stephen D; Chen, Xuejun; Liu, Cuiping; Shi, Wei; Geng, Hui; Foulds, Kathryn E; Kao, Shing-Fen; Noe, Amy; Li, Hui; Shaw, George M; Zhou, Tongqing; Petrovas, Constantinos; Todd, John-Paul; Keele, Brandon F; Lifson, Jeffrey D; Doria-Rose, Nicole A; Koup, Richard A; Yang, Zhi-Yong; Nabel, Gary J; Mascola, John R.
Afiliación
  • Pegu A; Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
  • Xu L; Sanofi, 640 Memorial Drive, Cambridge, MA, USA.
  • DeMouth ME; Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
  • Fabozzi G; Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
  • March K; Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
  • Almasri CG; Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
  • Cully MD; Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
  • Wang K; Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
  • Yang ES; Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
  • Dias J; Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
  • Fennessey CM; AIDS and Cancer Virus Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  • Hataye J; Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
  • Wei RR; Sanofi, 640 Memorial Drive, Cambridge, MA, USA.
  • Rao E; Sanofi, 640 Memorial Drive, Cambridge, MA, USA.
  • Casazza JP; Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
  • Promsote W; Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
  • Asokan M; Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
  • McKee K; Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
  • Schmidt SD; Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
  • Chen X; Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
  • Liu C; Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
  • Shi W; Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
  • Geng H; Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
  • Foulds KE; Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
  • Kao SF; Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
  • Noe A; Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
  • Li H; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Shaw GM; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Zhou T; Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
  • Petrovas C; Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
  • Todd JP; Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
  • Keele BF; AIDS and Cancer Virus Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  • Lifson JD; AIDS and Cancer Virus Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  • Doria-Rose NA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
  • Koup RA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
  • Yang ZY; Sanofi, 640 Memorial Drive, Cambridge, MA, USA.
  • Nabel GJ; Sanofi, 640 Memorial Drive, Cambridge, MA, USA. Electronic address: gary.nabel@modextx.com.
  • Mascola JR; Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA. Electronic address: jmascola@mail.nih.gov.
Cell Rep ; 38(1): 110199, 2022 01 04.
Article en En | MEDLINE | ID: mdl-34986348
ABSTRACT
Broadly neutralizing antibodies (bNAbs) represent an alternative to drug therapy for the treatment of HIV-1 infection. Immunotherapy with single bNAbs often leads to emergence of escape variants, suggesting a potential benefit of combination bNAb therapy. Here, a trispecific bNAb reduces viremia 100- to 1000-fold in viremic SHIV-infected macaques. After treatment discontinuation, viremia rebounds transiently and returns to low levels, through CD8-mediated immune control. These viruses remain sensitive to the trispecific antibody, despite loss of sensitivity to one of the parental bNAbs. Similarly, the trispecific bNAb suppresses the emergence of resistance in viruses derived from HIV-1-infected subjects, in contrast to parental bNAbs. Trispecific HIV-1 neutralizing antibodies, therefore, mediate potent antiviral activity in vivo and may minimize the potential for immune escape.
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Anticuerpos Anti-VIH / Síndrome de Inmunodeficiencia Adquirida del Simio / Virus de la Inmunodeficiencia de los Simios / Evasión Inmune / Anticuerpos ampliamente neutralizantes Límite: Animals / Humans Idioma: En Revista: Cell Rep Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Anticuerpos Anti-VIH / Síndrome de Inmunodeficiencia Adquirida del Simio / Virus de la Inmunodeficiencia de los Simios / Evasión Inmune / Anticuerpos ampliamente neutralizantes Límite: Animals / Humans Idioma: En Revista: Cell Rep Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos